The Alnylam Pharmaceuticals Inc (ALNY) share price is expected to increase by 37.1% over the next year. This is based on calculating the average 12-month share price estimate provided by 19 stock analysts who have covered ALNY. Price targets range from $135.00 at the low end to $395.00 at the high end. The current analyst consensus for ALNY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 19 Wall Street analysts have assigned ALNY 14 buy ratings, 5 hold ratings, and 0 sell ratings. This means that analysts expect Alnylam Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
leland gershell Oppenheimer | Hold | None | maintained | Feb 16, 2024 |
salveen richter Goldman Sachs | Hold | $173.0 | downgraded | Feb 15, 2024 |
tiago fauth Wells Fargo | Hold | $161.0 | maintained | Feb 15, 2024 |
andy chen Wolfe Research | Hold | None | initiatedcoverage | Feb 14, 2024 |
olivia brayer Cantor Fitzgerald | Hold | $165.0 | initiatedcoverage | Feb 12, 2024 |
anupam rama J.P. Morgan | Hold | $170.0 | maintained | Feb 1, 2024 |
mani foroohar Leerink Partners | Hold | $135.0 | reiterated | Jan 8, 2024 |
jessica fye J.P. Morgan | Hold | None | maintained | Dec 13, 2023 |
andrew galler Morgan Stanley | Hold | $183.0 | maintained | Nov 3, 2023 |
michael ulz Morgan Stanley | Hold | $183.0 | maintained | Nov 3, 2023 |
zhiqiang shu Berenberg Bank | Hold | $175.0 | maintained | May 4, 2023 |
david hoang SMBC Nikko | Hold | $220.0 | initiatedcoverage | Apr 26, 2023 |
matthew harrison Morgan Stanley | Hold | $220.0 | maintained | Oct 13, 2022 |
debjit chattopadhyay Guggenheim | Hold | None | downgraded | Jun 27, 2022 |
do kim Piper Sandler | Hold | $174.0 | maintained | Apr 30, 2021 |
etzer darout BMO Capital | Hold | $162.0 | downgraded | Feb 22, 2021 |
joel beatty Robert W. Baird | Hold | $175.0 | downgraded | Feb 12, 2021 |
navin jacob UBS | Hold | $87.0 | initiatedcoverage | Jan 23, 2019 |
jonathan block Stifel Nicolaus | Hold | $47.0 | reiterated | May 15, 2017 |
michael schmidt Guggenheim | Hold | $40.0 | reiterated | Oct 5, 2016 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2004
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Market Cap
$19.49B
In 2023, ALNY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ALNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$63.88
LPLA-USD
$257.66
DKNG-USD
$40.75
$80.04
ENTG-USD
$134.34
EXPE-USD
$134.64